Humacyte, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Humacyte, Inc. (Nasdaq: HUMA) develops and manufactures universally implantable, off-the-shelf, bioengineered human tissues and organs utilizing a proprietary scalable bioengineering platform that transforms human cells into acellular tissue engineered vessels (ATEVs) and advanced constructs designed to treat injury, disease, and chronic conditions with low infection rates and regenerative potential. Core products and investigational candidates include Symvess (acellular tissue engineered vessel-tyod), FDA-approved in December 2024 for extremity vascular trauma repair; ATEVs in Phase 3 for dialysis arteriovenous access (meeting co-primary endpoints in V007 trial), peripheral artery disease, coronary artery bypass grafting, and pediatric heart disease; advanced organ systems such as BioVascular Pancreas for type 1 diabetes and lung applications; and advanced tissue constructs for urinary conduits, tracheal replacement, and esophageal replacement. The company, founded in 2004 and headquartered in Durham, North Carolina, operates primarily in the United States with a global intellectual property footprint spanning the United States, Europe, Canada, and Australia; it targets vascular surgery, trauma centers, dialysis patients, military medical facilities, and regenerative medicine markets. Recent developments encompass the FDA's completion of Symvess product batch release review enabling commercial shipments, commencement of Symvess market launch and first sales in early 2025, a $46.7 million public offering to extend cash runway, cost reductions to align with commercial and pipeline priorities including a planned supplemental BLA for dialysis in H2 2026 and IND filing for CABG, and expansion of intellectual property in September 2025 with a new U.S. patent for bioengineered esophagus alongside coverage for trachea and urinary conduits to support pipeline advancement and potential corporate partnerships.
Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights
Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know
Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why
Here's Why Humacyte, Inc. (HUMA) Fell More Than Broader Market
Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet
Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know
Humacyte, Inc. (HUMA) Discusses V012 Study Top-Line Results for Engineered Vessel in Dialysis Access Transcript
Humacyte, Inc. (HUMA) Upgraded to Buy: Here's What You Should Know
Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients
Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients
Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Wall Street Bulls Look Optimistic About Humacyte, Inc. (HUMA): Should You Buy?
Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access
Humacyte Announces Symvess® is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs
Humacyte Q1 Earnings Call Highlights